Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Impairment Charges by Year
Impairment Charges ($M)
Novartis Impairment Charges: $557M in FY2025, up 6.5% from a year earlier.
Latest, FY2025
557
Period ended Dec 31, 2025
Change on a year earlier
+6.5%
523 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 10.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Impairment Charges ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 557 | +6.5% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 523 | -82.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 3,048 | +134.3% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2022 | Dec 31, 2022 | 1,301 | +246.0% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2021 | Dec 31, 2021 | 376 | -58.9% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2020 | Dec 31, 2020 | 914 | – | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
Cite this data
StockData. (2026). Novartis Impairment Charges ($M), annual FY2020–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ops-intang-impair
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.